(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 416.3% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Milestone Pharmaceuticals's revenue in 2024 is $1,000,000.On average, 1 Wall Street analysts forecast MIST's revenue for 2024 to be $95,669,600, with the lowest MIST revenue forecast at $95,669,600, and the highest MIST revenue forecast at $95,669,600. On average, 2 Wall Street analysts forecast MIST's revenue for 2025 to be $1,387,209,206, with the lowest MIST revenue forecast at $584,647,558, and the highest MIST revenue forecast at $2,189,770,854.
In 2026, MIST is forecast to generate $8,860,067,993 in revenue, with the lowest revenue forecast at $8,860,067,993 and the highest revenue forecast at $8,860,067,993.